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Background: The levels of serum low-density lipoproteins (LDL) have been implicated in the
inflammatory cascade in a murine model of asthma. Recent findings suggest that LDL may
modulate the inflammatory state of the asthmatic airways in humans.
Objective: We explored whether LDL subclasses are associated with the occurrence and
severity of asthma.
Methods: 24 asthmatics (M/F: 11/13) and 24 healthy individuals, with normal BMI and absence
of metabolic syndrome, matched for age and gender. Serum concentrations of LDL subclasses
were distributed as seven bands (LDL-1 and -2 defined as large, least pro-inflammatory LDL,
and LDL-3 to 7 defined as small, most pro-inflammatory LDL), using the LipoPrintª System
(Quantimetrix Corporation, Redondo Beach, CA, USA).
Results: LDL-1 was similar in the two groups (56  16% vs. 53  11, pZ NS), while LDL-2 was
significantly lower in asthmatics as compared to controls (35  8% vs. 43  10%, pZ 0.0074).
LDL-3 levels were two-fold higher in the asthmatics, but the difference did not reach the statis-
tical significance (8 7.3% vs. 4 3%, pZ NS). Smaller subclasses LDL-4 to LDL-7 were undetect-
able in controls. In asthmatics, LDL-1 was positively associated with VC% predicted (rZþ0.572,
pZ 0.0035) and FEV1% predicted (rZþ0.492, pZ 0.0146). LDL-3 was inversely correlated with
both VC% predicted (rZ 0.535, pZ 0.0071) and FEV1% predicted (rZ 0.465, pZ 0.0222).
Conclusions: The findings of this pilot study suggest a role of LDL in asthma, and advocate for
larger studies to confirm the association between asthma and dyslipidemia.
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Low density lipoproteins and asthma 1867Introduction MethodsThe pathogenesis of asthma is complex and involves a
condition of exaggerated airway response to stimuli, which
modulates the occurrence of the clinical manifestations,
and the remodeling changes of the airway wall compo-
nents. The latter are among the main responsible for the
non-reversible features of bronchial obstruction and the
blunted response to current treatments. These phenomena
are promoted and maintained by a condition of chronic
airway inflammation, which represents the cardinal feature
of asthma. In this regard, the pathways and mediators that
modulate the inflammatory response in asthma are still a
topic of research.
Recently, an apolipoprotein E (ApoE)-low density lip-
oproteic receptor pathway has been described as being
implicated in the pathogenesis of a murine model of
allergic asthma [1]. Although apolipoproteins play a key
role in lipid metabolism by serving as structural compo-
nents of plasma lipoproteins, for the mechanism whereby
these proteins modulate asthma pathogenesis and severity
has never been explored. In the cited experimental murine
model of asthma, airway hyperresponsiveness (AHR) and
goblet cell hyperplasia were increased in ApoE knock-out
mice, suggesting a role of ApoE as negative regulator of
AHR and goblet cell hyperplasia [1]. This novel observation
allowed to hypothesize that lipoproteins could play some
role in the manifestations of the inflammatory state of the
asthmatic airways also in humans.
It is known that cholesterol promotes Th2 immunity and
allergic inflammation in rodents [2]; whether this occurs in
humans is unclear [3,4]. Emerging evidence from animal
and cell experiments have shown anti-inflammatory ef-
fects of HDL consistent with a protective role in asthma
[5]. Recently, low levels of serum HDL were found to be
associated with an increased risk for asthma in adoles-
cence, suggesting a potential role of this lipoprotein in
the pathogenesis of pediatric asthma [6]. However, the
association between LDL and asthma has not been
investigated.
On the basis of density or size, determined by ultra-
centrifugation or polyacrylamide gradient gel electropho-
resis (GGE), up to 7 distinct LDL subclasses can be
distinguished [7,8]. Smaller LDL sizes means increased
oxidative susceptibility and decreased antioxidant con-
centrations. Small LDL lead to retarded metabolism and
decreased intra-extravascular equilibration compared to
medium sized LDL [9]. In addition, it is known that oxidized
LDL (oxLDL) directly interacting with proinflammatory
signal pathways in vascular cells and monocytes/macro-
phages [10]. The macrophages “present the antigen” to T
lymphocytes and this antigen may be a fragment of oxLDL
“digested” by the macrophages [11]. Lately it has been
emphasized that adaptive immune responses have an
importance in the regulation of inflammation [12] and T
cells specifically recognize epitopes in oxLDL [13].
We first explored whether the serum concentrations of
the LDL subclasses were abnormal in untreated asthmatics
compared to non-asthmatics. As a secondary aim, we
assessed whether changes in the lipoprotein pattern were
associated with lung function impairment in asthmatics.Study subjects
We enrolled consecutive, not smoker individuals with
normal body mass index and absence of metabolic syn-
drome, who fulfilled the diagnostic criteria for asthma [14].
Asthmatics were recruited from the Outpatient Clinic for
Respiratory Diseases section of DiBiMIS of the University of
Palermo, Italy. All subjects had history of asthma with a
positive reversibility test to confirm the diagnosis. All of
them were positive to skin test for perennial aeroallergens.
When sensitization to pollens was also present, subjects
were tested out of season. None of them had suffered an
exacerbation within the three months preceding the study,
and all were clinically stable at the time of the study.
Subjects were asked to refrain from taking asthma drugs for
two weeks before the study visit, to avoid any influence of
inhaled corticosteroids on the lipid profile, and only rescue
medications were allowed during the wash-out period.
Healthy, not smoker individuals, with normal body mass
index and matched for age and gender were recruited from
co-workers to serve as healthy controls. Their lung function
was always within normal values, and all of them denied
any respiratory symptom suggestive of chronic respiratory
diseases. None of the subjects was receiving statins. The
study was performed in accordance with the Good Clinical
Practice guidelines recommended by the International
Conference on Harmonization of Technical Requirements
and was approved by the Ethics Committee of the Univer-
sity of Palermo, Palermo, Italy (April 5, 2012); written
informed consent was obtained from each volunteer.
Study design
The study was conducted in one visit, and included clinical
and functional assessments, as well as measurements
of serum concentrations of the lipid composition (LDL
subclasses).
Clinical and functional assessments
We recorded clinical and demographic data including age,
sex, duration of disease, frequency of exacerbations in the
previous year. Laboratory tests included total cholesterol,
LDL- and HDL-cholesterol, and tryglicerides. Functional
assessment included measures of static and dynamic lung
volumes, using computerized water-sealed spirometry and
helium dilution technique (Biomedin; Padua, Italy). Mea-
surements were made in accordance to the European
Thoracic Society standardisation of lung volume measure-
ments [15]. FEV1% predicted and FVC% predicted, as well as
TLC % predicted and RV% predicted, were calculated and
used for the analysis.
LDL subclass analysis
Blood samples were obtained at rest after fasting overnight;
blood was drawn from the subject’s antecubital vein
into sterile tubes. Serum was separated and stored for
Table 1 Demographic and lung function characteristics of
the asthmatics.












1 F 45 86 71 70.9 92 86 107
2 F 22 111 99 77.6 134 118 113
3 F 35 113 116 89.5 139 133 115
4 M 33 82 79 76.5 83 82 98
5 M 58 108 105 74.7 152 120 119
6 F 38 109 105 83.8 87 100 87
7 M 40 73 67 73.1 58 68 84
8 M 55 65 52 61.8 87 71 118
9 M 59 102 110 82.7 86 94 89
10 M 61 92 105 85.9 82 86 90
11 F 48 114 89 67.0 72 95 77
12 M 74 101 109 79.4 163 122 127
13 F 36 120 102 73.4 142 126 112
14 M 61 89 72 62.2 91 88 105
15 F 53 111 101 78.4 95 99 97
16 F 64 111 77 58.5 99 98 100
17 M 44 99 94 74.6 94 97 96
18 F 40 117 107 79.1 102 110 93
19 F 57 88 79 76.5 123 96 133
20 F 55 107 83 66.1 86 94 89
21 M 31 94 74 63.5 95 94 100
22 F 59 112 121 91.0 99 100 98
23 M 64 102 78 58.2 108 102 106
24 F 52 98 93 80.7 137 108 125
Figure 1 Histograms showing the single bands of LDL sub-
classes in asthmatic and healthy subjects. **p < 0.01.
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gel electrophoresis was used to separate and measure LDL
subclasses, with the LipoPrintª System (Quantimetrix Cor-
poration, Redondo Beach, CA, USA) [16]. This method has
been validated against gradient gel electrophoresis and
nuclear magnetic resonance and it is the only Food and Drug
Administration-cleared diagnostic tool for lipoprotein sub-
fraction testing in the USA [17]. The electrophoresed gels
were scanned to determine the relative area of each lip-
opoprotein subfraction. The diagnostic procedure was per-
formed for 60 min with 3 mA for each gel tube [18]. Each
electrophoresis chamber involved two quality controls. For
quantification, scanning was performed with a digital
scanner and a Mac personal computer (Apple Computer Inc,
USA). After scanning, electrophoretic mobility and the area
under the curve were calculated qualitatively and quanti-
tatively. LDL subclasses were distributed as seven bands
(LDL-1 to LDL-7, respectively), in consistency with the data
that can be obtained by gradient gel electrohoresis [9]. LDL-
1 and -2 are defined as large LDL; LDL-3 to 7 are defined as
small LDL.[18].
Statistical analysis
Statistical analysis was performed using Statview 5.0
(SAS Institute Inc., Cary, NC, USA). Univariate analysis was
performed using non-parametric ManneWhitney test for
numeric variables, while the differences in the prevalence
for nominal variables were analysed by the McNemar test.
Correlation analysis was performed using the Spearman
rank correlation method. Multivariate analysis was per-
formed to establish whether the significant correlations
between LDL subclasses and lung parameters, as assessed
by univariate analysis, remained significant after cor-
recting for age, gender and BMI. Given the explorative
nature of this pilot study, no power calculation was
performed.
Results
A total of 24 asthmatics (M/F: 11/13) and 24 healthy sub-
jects (M/F: 11/13) were enrolled. Five asthmatics were
receiving inhaled corticosteroids, which were stopped two
weeks prior to the study visit. In the asthmatic group, FEV1
% predicted was 91  18% (mean  SD, range: 52e121%), VC
% predicted was 100  14% (range: 82e112%), and FEV1/FVC
was 74  9% (range: 58e91%). Individual lung function
characteristics of the asthmatics are presented in Table 1.
Fig. 1 shows the single bands of LDL subclasses obtained
with the applied method in asthmatics and healthy sub-
jects. By LDL subclass analysis we found that LDL-1 was
similar in the two groups (56  16% vs. 53  11, p Z NS),
while LDL-2 was significantly lower in asthmatics as
compared to controls (35  8% vs. 43  10%, p Z 0.0074).
Conversely, LDL-3 levels were two-fold higher in the asth-
matics, but the difference did not reach the statistical
significance (8  7.3% vs. 4  3%, p Z NS). Furthermore,
smaller subclasses LDL-4 to LDL-7 were undetectable in
controls, while the asthmatics had little presence of LDL-4
(2  4%) and traces of LDL-5 and LDL-7 (0.2  0.7% and
0.2  0.8%, respectively). This is summarized in Table 2.In the asthmatic group, we performed correlation anal-
ysis between LDL subclasses and lung function parameters.
LDL-1 was positively associated with VC% predicted
(r Z þ0.572, p Z 0.0035) and FEV1% predicted
(r Z þ0.492, p Z 0.0146) (Fig. 2, panels A and C).
Conversely, LDL-3 was inversely correlated with VC% pre-
dicted (r Z 0.535, p Z 0.0071) and FEV1% predicted
(r Z 0.465, p Z 0.0222) Fig. 2, panels B and D). In
addition, TLC % predicted positively correlated with LDL-1
(r Z þ0.585, p Z 0.0026) and inversely with LDL-2 and
LDL-3 (r Z 0.412, p Z 0.0237 and r Z 0.485,
p Z 0.0163, respectively). Neither RV nor RV/TLC signifi-
cantly correlated with LDL subclasses (Table 3). Finally, no






Females, n (%) 13 (54) / 13 (54)
Age (years) 49  13 0.8 50  11
Body Mass
Index (kg/m2)
25  3 0.4 26  4
Smoking, n (%) 9 (38) 0.8 10 (42)
Total Cholesterol
(mg/dL)
184  31 0.0009 151  28
Triglycerides
(mg/dL)
119  62 0.1 95  38
LDL-cholesterol
(mg/dL)
108  25 0.0002 79  22
HDL-cholesterol
(mg/dL)
50  13 0.6 53  13
LDL-1 (%) 56  16 0.3 53  11
LDL-2 (%) 35  8 0.0074 43  10
LDL-3 (%) 8  7 0.09 4  3
LDL-4 (%) 2  4 0.2 0  0
LDL-5 (%) 0.2  0.7 0.8 0  0
LDL-6 (%) 0  0 e 0  0
LDL-7 (%) 0.2  0.8 0.8 0  0
Figure 2 Spearman correlations between VC % predicted and L
r Z 0.535, p Z 0.0071), as well as between FEV1 % predicted and
r Z 0.465, p Z 0.0222).
Low density lipoproteins and asthma 1869relationship was detected between LDL subclasses and the
rate of exacerbation in the previous year. The significant
correlations involving LDL-4 and LDL-5 (Table 3), should be
taken into account with caution since these LDL subclasses
were mostly undetectable in the asthmatic group (Table 2).
Multivariate analysis was performed to establish
whether the significant correlations between LDL sub-
classes and lung parameters remained significant after
correcting for age, gender and BMI. The analysis confirms
the positive association of LDL-1 with VC % predicted and
the negative association of LDL-3 with FEV1 % predicted, as
well as the association of TLC% predicted with LDL-1 and
LDL-2.
Discussion
The lung has never been considered as an organ sensitive to
circulating lipoproteins and their cholesterol cargo. How-
ever, recent findings have suggested an important and,
perhaps, unique role for lipoproteins and cholesterol in
pulmonary physiology and pathophysiology. The findings of
this pilot study suggest a role of low density lipoproteins in
asthma. In asthmatics, the least pro-inflammatory LDL
(LDL-1 and LDL-2) appear to be lower, and the most pro-
inflammatory (LDL-3 and LDL-4) higher, compared to
healthy controls, although the difference did not always
reached significance. In addition, the serum concentrationsDL-1 (Panel A: r Z þ0.572, p Z 0.0035) and LDL-3 (Panel B:
LDL-1 (Panel C: rZ þ0.492, pZ 0.0146) and LDL-3 (Panel D:
Table 3 Spearman correlations between LDL subclasses and lung volumes. In bold the relationships that reached statistical
significance (p < 0.05). *This relationship remained significant when adjusted for gender, age and body mass index.
Parameter LDL-1 LDL-2 LDL-3 LDL-4 LDL-5 LDL-6 LDL-7
VC % predicted 0.572* 0.331 0. 535 0.539 0.529 / 0.133
FEV1 % predicted 0.492 0.288 0.465* 0.473 0.471 / 0.166
FEV1/VC 0.326 0.195 0.302 0.341 0.288 / 0.215
RV % predicted 0.346 0.231 0.278 0.290 0.138 / 0.138
TLC % predicted 0.585* 0.419* 0.485 0.468 0.375 / 0.007
RV/TLC % predicted 0.031 0.010 0.067 0.042 0.215 / 0.237
1870 N. Scichilone et al.of the LDL-1 (least pro-inflammatory) positively correlated
with lung function, whereas the serum concentrations of
LDL-3 (most pro-inflammatory) were negatively associated
with lung function.
The activation of the innate immune system by choles-
terol overload has only recently been examined in the
context of the lung [2,19e23]. Circulating LDL and HDL are
both taken up by the lung through specific receptors, and
supply cholesterol to lung-resident cells, thereby inhibiting
local pulmonary cholesterol biosynthesis. Although choles-
terol is essential for type II cell function, excessive amounts
of cholesterol impair surfactant function, suggesting the
critical importance of alveolar cholesterol homeostasis to
normal lung physiology [24e27]. Several experimental
studies describing the pathogenic role of Th1 immunity
based on induction of disease by hypercholesterolemia
suggest that the relevant autoantigen is a lipoprotein or
possibly a protein modified by lipids. Most attention has
focused on the role of LDL in these processes and strong
evidence for the existence of autoimmune responses
against LDL has been provided [28]. In this context, Akdis
et al. have reported that in allergy and asthma, the balance
between the Th1, Th2 and T regulatory cytokine responses
appears to be shifted towards Th2, and that synthetic lip-
opeptides (which contain the typical lipid part of the lipo-
protein of gram-negative bacteria) stimulate a particular
regulatory cytokine pattern (abundant levels of IL-10 and
IFN- g) and inhibit several Th2 cell-related phenomena
(including IgE production and eosinophilia) [29]. Similarly,
ongoing studies point out to the T cells as the most likely
candidate for the alternative protective immune pathway
and the possibility of developing immune-modulating
therapy for prevention of cardiovascular disease [28].
These observations led us to explore the role of
lipoproteins in asthma. By discriminating among different
subclasses, we were able to demonstrate that larger LDL
subclasses, specifically LDL-2, were diminished in asthmatic
subjects, as opposed to healthy controls, perhaps inducing
a shift towards the production of the atherogenic, small
LDL, leading to the amplification of the inflammatory
cascade in asthma. At this stage, we can only infer on
causative relationships between pro-inflammatory compo-
nents and impairment in lung function. The positive rela-
tionship between the least pro-inflammatory LDL subclasses
and lung function, and the negative association between
the most pro-inflammatory LDL and lung function strongly
suggest that LDL are a potent trigger for the inflammatory
changes of the airways. The apparent contradictory
behavior of LDL-2 in relation to lung function deservesspeculation. The relatively small number of asthmatics
included might be a reason for the difference with regard
to lung function parameters (LDL-1 and -2). On the other
hand, the different association with lung function param-
eters might indicate a shift towards the production of the
atherogenic, small LDL, leading to the amplification of the
inflammatory cascade in asthma, or might envisage a
‘transition state’ with disease progression. However, these
explanations need further specifically designed studies.
The available literature indicates that severe hyper-
cholesterolemia can induce a switch of autoimmune re-
sponses from Th1 to Th2 effector type in apoE knockout
(E0) mice [30]. This could either be due to a direct effect of
the hypercholesterolemic state on immune activity or to a
metabolic change caused by the high-cholesterol diet [31].
The diet-induced dyslipidemia has been shown to induce a
dysregulated compartmentalization of neutrophils and cy-
tokines between serum and airspace, enhancing host de-
fenses in the former but compromising host defense in the
latter [32,33]. Recently, Yao et al. [1,34] applied an
experimental model of house dust mite (HDM)-induced
murine asthma to identify pulmonary genes that are upre-
gulated in response to HDM challenge, and remain persis-
tently upregulated despite corticosteroid treatment. In
HDM-challenged mice, genome-wide expression profiling
of the asthmatic lung transcriptome identified ApoE as a
steroid-unresponsive gene with persistently upregulated
expression despite steroid treatment. ApoE knockout mice
develop hypercholesterolemia and spontaneous athero-
sclerosis. Interestingly, the dyslipidemic murine strains
were recently reported to display increased airway hyper-
responsiveness and mucus production but normal airway
inflammatory cell counts. These observations could carry
clinical implications. Administration of an ApoE mimetic
peptide prevented the induction of airway inflammation,
airway hyperreactivity, and goblet cell hyperplasia in HDM-
challenged E0 mice. Schafer et al. [35] investigated, in a
caseecontrol fashion, the relationship between serum
cholesterol levels and clinical manifestation of atopy. The
total and LDL levels were inversely associated with the
frequency of allegic rhinoconjunctivitis and allergen sensi-
tization, whereas positive associations were found between
HDL levels and frequency of allergic rhinoconjunctivitis and
atopic eczema.
Our findings could be supported by the suggested
benefit of statins on asthma symptoms through their anti-
inflammatory effect [36,37]. Accordingly, a large pro-
spective population-based cohort study (the Rotterdam
Study) reported the lower risk of death in chronic
Low density lipoproteins and asthma 1871obstructive pulmonary disease (COPD) patients using sta-
tins [38]. The recent meta-analysis shown that even a sub-
population of asthmatics, including smokers and obese
individuals who respond poorly to inhaled corticosteroids
may respond preferentially to statins [39]. However, it
seems that statins do not to have any additional benefit in
asthma control or steroid-sparing effect in asthma treat-
ment [40]. Nevertheless, most recent in vitro study shown
that lovastatin attenuates both TGF-b1-induced pheno-
typic transdifferentiation of asthmatic bronchial fibro-
blasts into myofibroblasts in culture and human bronchial
fibroblasts proliferation [41]. Also, rosuvastatin is a potent
inhibitor of human airway smooth muscle cells growth
induced by different mitogenic stimuli [42]. Both simva-
statin and atorvastatin treatment reduced leukocytes and
leukotrienes in sputum, as well an improvement in FEV1
[43,44]. Some authors highlighted the mevalonate-
dependent and -independent pathways that may be
modulated by statins as an opportunity to develop new
treatments for asthma [45].
In conclusion, the findings of the current study propose a
role of LDL in asthma. The elucidation of the mechanism by
which this occurs, and the relationship between dyslipide-
mia and asthma need specifically designed studies.
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